# Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children

> **NCT01333813** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 300 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix-B™ Kinder

## Key facts

- **NCT ID:** NCT01333813
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-26
- **Primary completion:** 2011-09-28
- **Final completion:** 2011-09-28
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333813, "Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01333813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*